已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies

医学 代理终结点 内科学 随机对照试验 肿瘤科 无进展生存期 恶性肿瘤 总体生存率 黑色素瘤 癌症研究
作者
Adel Shahnam,Nadia Hitchen,Udit Nindra,Sathya Manoharan,Jayesh Desai,Ben Tran,Benjamin Solomon,Stephen J. Luen,Rina Hui,Ashley M. Hopkins,Michael J. Sorich
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:198: 113503-113503 被引量:6
标识
DOI:10.1016/j.ejca.2023.113503
摘要

Background Overall survival (OS) results from randomized control trials (RCT) provide the strongest evidence for efficacy of anti-cancer treatments but can take a considerable amount of time to mature. Progression free survival (PFS) and objective response rate (ORR) are used as an early surrogate of OS treatment effect however their validity remains unclear. Our study aims to comprehensively evaluate ORR and PFS as surrogates for OS treatment effect across tumor groups and treatment types. Material and Methods Phase 3 RCTs in solid malignancies that reported OS/PFS and ORR published between 1st of January 2010 and 30th of June 2022 were evaluated. The relationship of surrogate endpoints and OS treatment effect was assessed via weighted linear regression. The coefficient of determination (R2) quantified the fit of the regression model. Results 675 phase 3 RCT comprising of 350 112 patients were analysed. ORR (R2 of 0.10) and PFS (R2 of 0.38) were poor surrogate markers of OS treatment effect. The strength of surrogacy differed within treatment and tumour groups. PFS had the highest R2 for chemotherapy (0.56) and lowest for targeted therapy (0.40). PFS had the highest level of surrogacy for melanoma (R2 = 0.72) and pancreatic cancer (R2 = 0.70) compared to other tumour groups. Importantly ORR and PFS were also poorly correlated to each other (R2 = 0.33). Conclusions ORR and PFS were poor trial-level surrogate markers of OS. The surrogacy performance of ORR and PFS differed by treatment and malignancy sub-type.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小真白发布了新的文献求助10
刚刚
充电宝应助科研通管家采纳,获得10
1秒前
SciGPT应助科研通管家采纳,获得10
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
aldehyde应助科研通管家采纳,获得10
1秒前
1秒前
大模型应助科研通管家采纳,获得10
1秒前
科研通AI5应助科研通管家采纳,获得50
1秒前
1秒前
Owen应助科研通管家采纳,获得10
1秒前
清欢完成签到,获得积分10
5秒前
Li发布了新的文献求助10
6秒前
Jasonjoey完成签到,获得积分10
8秒前
9秒前
天天快乐应助Li采纳,获得10
12秒前
大个应助悠悠我心采纳,获得30
13秒前
小冠军完成签到,获得积分10
13秒前
15秒前
害羞便当完成签到 ,获得积分10
15秒前
情怀应助小刘采纳,获得10
16秒前
zhouleiwang发布了新的文献求助10
16秒前
斯文败类应助bing采纳,获得10
18秒前
大胆灵竹发布了新的文献求助10
21秒前
24秒前
希望天下0贩的0应助sigrid采纳,获得10
27秒前
完美世界应助淡定的半梦采纳,获得10
30秒前
ding应助很好采纳,获得10
30秒前
bing发布了新的文献求助10
31秒前
33秒前
弧光完成签到 ,获得积分0
33秒前
bing完成签到,获得积分10
35秒前
HLZ发布了新的文献求助10
37秒前
lmk完成签到 ,获得积分10
40秒前
47秒前
踏实的碧空完成签到 ,获得积分10
47秒前
压缩完成签到 ,获得积分10
50秒前
很好发布了新的文献求助10
52秒前
缓慢的灵枫完成签到 ,获得积分10
54秒前
56秒前
58秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989989
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256053
捐赠科研通 3270900
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216